A Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia (MTP-131) in Patients With Heart Failure Due to Reduced Left Ventricular Ejection Fraction

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia (MTP-131) in Patients With Heart Failure Due to Reduced Left Ventricular Ejection Fraction

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 14 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
    • 24 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top